Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Biesen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Rheumatologie|September 30, 2011
[DNA microarrays]R Biesen, T Häupl
Der Internist|October 2, 2014
[Rheumatoid factor or antinuclear antibodies as incidental finding]R Biesen, G-R Burmester, F Hiepe
Lupus|June 3, 2016
Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLER Biesen, T Rose, B F Hoyer, et al.
Zeitschrift Fur Rheumatologie|January 16, 2009
[Systemic lupus erythematosus. Target criteria for treatment]T Alexander, R Biesen, A Jacobi, et al.
Scandinavian Journal of Rheumatology|November 2, 2021
Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapyR Biesen, M Frese-Schaper, P Enghard, et al.
Clinical and Experimental Immunology|October 7, 2015
Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodiesV Jucaud, M H Ravindranath, P I Terasaki, et al.
Arthritis and Rheumatism|January 1, 2009
CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patientsP Enghard, J Y Humrich, B Rudolph, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 24, 2023
Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization testsE Habermann, L M Frommert, K Ghannam, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Rheumatologie|September 30, 2011
[DNA microarrays]R Biesen, T Häupl
Der Internist|October 2, 2014
[Rheumatoid factor or antinuclear antibodies as incidental finding]R Biesen, G-R Burmester, F Hiepe
Lupus|June 3, 2016
Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLER Biesen, T Rose, B F Hoyer, et al.
Zeitschrift Fur Rheumatologie|January 16, 2009
[Systemic lupus erythematosus. Target criteria for treatment]T Alexander, R Biesen, A Jacobi, et al.
Scandinavian Journal of Rheumatology|November 2, 2021
Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapyR Biesen, M Frese-Schaper, P Enghard, et al.
Clinical and Experimental Immunology|October 7, 2015
Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodiesV Jucaud, M H Ravindranath, P I Terasaki, et al.
Arthritis and Rheumatism|January 1, 2009
CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patientsP Enghard, J Y Humrich, B Rudolph, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 24, 2023
Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization testsE Habermann, L M Frommert, K Ghannam, et al.
Pageof 1